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This study evaluated the effects of a combined ethanolic extract of Funtumia africana and 
Abutilon mauritianum leaves (CFAAM) on the sex steroid hormone levels and prostate 
indices of benign prostatic hyperplasia (BPH) induced rats to validate their anti-BPH 
activities as claimed by traditional medicine healers.  30 male Wistar albino rats were 
randomly divided into 5 groups. Group 1 served as the normal control that received 
normal saline and olive oil only, while groups 2 – 5 were BPH induced. Group 2 was the 
BPH control, group 3 was treated with 5 mg/kg/d Finasteride, while groups 4 and 5 were 
treated with 200 and 600 mg/kg/d CFAAM respectively for 28 days. BPH induction 
caused significant (p<0.05) increases in the concentrations of testosterone, 
dihydrotestosterone and estradiol, increased prostate weight and prostate index in the 
BPH control when compared with the normal control. Treatment with CFAAM significantly 
(p<0.05) reversed the increased testosterone, dihydrotestosterone and estradiol levels, 
prostate weight, and prostate indices in comparison with the BPH control. This study 
revealed that the CFAAM ameliorate adverse effects of benign prostatic hyperplasia in 
rats and may be useful in the management of individuals with benign prostatic 
hyperplasia.  
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Benign prostatic hyperplasia (BPH) is a non-
malignant prostate disease due to uncontrolled 
differentiation and proliferation of the prostate 
epithelial and stromal tissues mostly in senile 
men above 40 years (Nicholson and Rick, 2011). 
Although it is generally believed to occur in 
ageing men, it is common in some family which 
indicates that there are inheritable genetic 
factors that predispose some ageing men to the 
development of BPH. Patients with BPH 
experience increased frequency of urination, 
reduced urinary flow, and incomplete emptying 
of the bladder. Imbalance in the circulating 
levels of sex hormones including testosterone, 
dihydrotestosterone (DHT) and oestrogens have 
been implicated as the risk factors in the 
pathogenesis of BPH (McPherson et al., 2008; 
Wilson, 2011). Studies have established that 
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patients with BPH have a very high level of DHT 
in serum (Ryl et al., 2015). DHT induces 
prostate growth and inhibits the conversion of 
testosterone by 5α-reductase, limits the level of 
DHT, prevents prostate enlargement and 
reduces prostate weight by at least 30 % 
(Andriole et al., 2004; Nickel et al., 2011). The 
aetiology and mechanisms of pathogenesis of 
benign prostatic hyperplasia are not fully 
understood but many researchers in this field 
believe that increased secretion and 
accumulation of DHT level in the prostate 
tissues with ageing is responsible for the 
initiation of increased prostate cell growth and 
prostatic hyperplasia (Bartsch et al., 2000; 
Carson and Rittmaster, 2003). Treatment of 
patients with BPH is mainly by 5α-reductase 
inhibitors such as Finasteride and dutasteride 
that block the conversion of testosterone to a 
more potent DHT. Other proven therapeutics 
are α-adrenoceptors antagonists including 
doxazosin and tamsulosin, but there are many 
adverse side effects associated with their usage 
(Patel and Chapple, 2008). Many traditional 
medicines of plant origin have been successfully 
used to treated BPH patients with total recovery 
but are rarely documented in the scientific 
literature. 
Funtumia africana (Benth.) is a potent 
medicinal plant of Apocynaceae family 
commonly called “Furu” by the Yoruba and 
“Mbamiri” by the Igbo speaking tribes of 
Nigeria. It has been used in the treatment of 
many diseases including cancer, malaria, 
dysentery, diabetes, bacterial infections, 
hypertension, inflammation, wounds, urinary 
incontinence and oedema (Odugbemi et al., 
2007; Ashidi et al., 2010; Ramadwa et al., 
2017). 
Abutilon mauritianum (Jacq.) is 
commonly known as African mallow in English, 
“Akoire” in Yoruba and “Kawo” in Igbo is a 
member of the Malvaceae family that has 
demonstrated various medicinal potentials and 
constitute part of major herbal formulation in 
West African traditional medicine especially in 
the south-eastern part of Nigeria. It has been 
reported that various herbal formulations with 
A. mauritianum parts are used in the treatment 
of diarrhoea, gonorrhoea, cough, pile and as 
antipyretic (Olowokudejo et al., 2008). The 
members of the genus Abutilon are used to 
treat malaria (Beha et al., 2004), snakebite 
(Shrikanth et al., 2011), Viral diseases 
(Mohamed et al., 2010), ulcer (Ponnudurai et 
al., 2011) and wound healing (Suresh et al., 
2011).  
Extracts of F. africana leaves have been 
reported to be rich in saponins, flavonoids, 
tannins, polyterpenes, polyphenols terpenoids, 
steroids, cardiac glycosides and alkaloids and 
many of their pharmacological activities are 
attributed to these phytochemical constituents 
(Kouadio et al., 2017; Nwandu et al., 2019).  
Similarly, the pharmacological activities of A. 
mauritianum leaf extract are attributed to its 
rich contents of steroids, saponins, tannins, 
phenols, alkaloids and flavonoids (Banso and 
Adeyemo, 2004). The combined ethanol extract 
of F. africana and A. mauritianum leaves is 
relatively safe for consumption with LD50 value 
of above 5,000 mg/kg (Uroko et al., 2020).  
The various medicinal properties of 
these plant extracts prompted this study to 
evaluate the effects of CFAAM on the sex 
steroid hormone levels and prostate indices in 
benign prostatic hyperplasia induced rat.  
 
MATERIALS AND METHODS 
 
Collection and Identification of Plant 
Materials: Funtumia africana and Abutilon 
mauritianum leaves were used in this study. The 
fresh leaves of F. africana and A. mauritianum 
were sourced from the Forestry Research 
Institute of Nigeria, Eastern Station, Ahia-Eke 
Ndume, Umuahia, Abia State. The plants were 
identified and authenticated as F. africana and 
A. mauritianum with voucher numbers 2694-5 
[Preuss 1899] and Jones FHI 13749 respectively 
by a plant taxonomist at the Department of 
Forestry, College of Natural Resources and 
Environmental Management, Michael Okpara 
University of Agriculture, Umudike, Abia State, 
Nigeria. The plant samples were handpicked, 
rinsed in clean running water and dried under 
shade till constant weights were obtained. The 
dried plant samples were pulverised into coarse 
powders using a mechanical grinder and stored 
in clean plastic containers.   
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Ethical Issues: The experimental procedures 
employed in the study carefully adhered to the 
guidelines stipulated by the National Institute of 
Health’s guidelines for the care and use of 
animals for research (ILAR, 1986) and the 
guidelines of the Research Ethics Committee of 
Michael Okpara University of Agriculture, 
Umudike for experiments with animals. The 
ethical clearance was duly obtained from the 
Ethical Committee of the Department of 
Physiology and Pharmacology, College of 
Veterinary Medicine, Michael Okpara University 
of Agriculture, Umudike with the Ethical 
Clearance Number - MOUAU/VPP/EC/18/003. 
 
Experimental Animals: Thirty (30) male 
Wistar albino rats aged between 15 – 16 weeks 
and weighing 100 – 120 g were purchased from 
the Animal House, Department of Zoology and 
Environmental Biology, Faculty of Biological 
Sciences, University of Nigeria Nsukka, Nigeria. 
The rats were kept on a standard laboratory 
diet (Vital feed) and drinking water ad libitum 
and acclimatized under a 12 hour light/dark 
cycle for 14 days before the commencement of 
the experimental study.  
 
Formulation of a Combined Extract: The 
combined extract was formulated using coarsely 
ground Funtumia africana and Abutilon 
mauritianum leaves in the ratio of 1:1 (i.e. 250 
g each, equivalent to 500 g of both plant 
samples). The decision to combine the plants in 
a ratio of 1:1 for extraction was to mimic their 
local use in traditional medicine though there 
was no literature to support it. Each dosage was 
20 times reduction of the LC50 earlier reported 
as safe (Uroko et al., 2020). The combined 
plant powders were extracted by dissolving it 
1.5 L of absolute ethanolic for 72 hours. After 
which it was filtered and concentrated till the 
ethanolic solvent was completely evaporated in 
the water bath at 45℃ and the percentage yield 
calculated.  
  
Experimental Design: The study used 
completely randomised design (CRD) of five 
treatment groups, replicated thrice with each 
replicate having two rats.  The 30 rats were 
randomly grouped into five groups, Group 1 
served as the normal control without BPH 
induction, whereas group 2 served as BPH 
control that was BPH induced untreated. Group 
3 served as the standard control that BPH 
induced but treated with 5 mg/kg/d Finasteride 
for 28 days while groups 4 and 5 were BPH 
induced rats treated with 200 and 600 mg/kg/d 
CFAAM respectively. Benign prostatic 
hyperplasia (BPH) was induced in the rats by 
subcutaneous injection of testosterone 
propionate in olive oil (2:1 v/v) (5 mg/kg/d) for 
28 days consecutively. Treatments were given 
to the rats one hour after testosterone 
administration every day for 28 days 
consecutively. The body weights (BW) of the 
rats were recorded every week throughout the 
study period. After the last administration of 
testosterone propionate and treatments on the 
28th day, the rats fasted overnight. The rats 
were anaesthetized by the intraperitoneal 
administration of a low dose of pentobarbital 
(25 mg/kg) and allowed to stay for 10 minutes 
before blood samples were collected from the 
rats through cardiac puncture and prostate 
tissues harvested and weighed on the 29th day. 
   
Determination of Prostate Weight (PW) 
and Prostate Index (PI): The prostate 
weight and prostate index were determined 
according to the methods of Cai et al. (2018). 
Prostate weight (PW) and body weight (BW) of 
the rats were recorded in each group. The 
prostate index was calculated as PI (%) = 
PW/BW x 100 and the mean PI ratio was 
calculated for each group. The percentage 
inhibitions of PW and PI were calculated as 100 
– T({T – C}/{B – C} x 100), where C, B and T 
were the values of the normal control group, 
BPH control and treatment group respectively. 
 
Determination of Testosterone (TT), 
Dihydrotestosterone (DHT) and Estradiol 
(E2) Concentrations: The serum testosterone, 
dihydrotestosterone and estradiol concentrations 
were determined using the methods described 
by Tietz (1995). The principle of this assay is 
based on competitive binding between 
testosterone in the test specimen and 
testosterone-horseradish peroxidase (HRP) 
conjugate for a constant amount of rabbit anti-
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testosterone in the incubation. Goat anti-rabbit 
IgG-coated wells were incubated with 
testosterone standards and sample, 
testosterone-HRP conjugate reagent and rabbit 
anti-testosterone reagent for 90 minutes. The 
serum concentrations of dihydrotestosterone 
(DHT) were determined with an enzyme-linked 
immunosorbent assay (ELISA) kit using the 
instructions outlined by the manufacturer 
(AMEKO Incorporated, China) and the 
concentrations obtained expressed as ng/mL 
(Tietz, 1995).  
The estradiol was assayed using 
immunoassay which required an antibody, 
enzyme-antigen conjugate and the native 
antigen as essential reagents. The principle of 
assaying for estradiol using immunoassay is 
because when a biotinylated antibody is mixed 
with a serum containing the antigen, a reaction 
occurs between the antigen and the antibody. 
After a short incubation, the enzyme conjugate 
is added, competition reaction results between 
the enzyme analogue and the antigen in the 
sample for a limited number of antibody binding 
sites (not consumed in the first reaction). A 
simultaneous reaction between the biotin 
attached to the antibody and the streptavidin 
immobilized on the microwell occurs. This 
effects the separation of the antibody-bound 
fraction after decantation or aspiration. The 
enzyme activity in the antibody-bound fraction 
is inversely proportional to the native antigen 
concentration (Tietz, 1995). 
 
Statistical Analysis: The data generated from 
this study were analysed with one-way analysis 
of variance (ANOVA) and Duncan’s multiple 
comparison post hoc test using Statistical 
Package for Social Sciences (SPSS) Version 22. 
The level of statistical significance was 




Percentage Yield of the Combined Extract: 
The extraction of 500 g of the combined plant 
samples gave a percentage yield of 4.23 % 
equivalent to 21.15 g of the CFAAM.  
 
Effects of Combined Ethanolic Extract of F. 
africana and A. mauritianum Leaves 
(CFAAM) on the Body Weight of Benign 
Prostatic Hyperplasia (BPH) Induced Rats: 
It was observed that the body weights of the 
normal control and BPH control rats showed no 
significant (p>0.05) increases after week 2, and 
significant (p<0.05) after weeks 3 and 4, 
respectively when compared with their 
respective body weight at week 1 (Table 1). 
However, standard control, and BPH induced 
rats treated 200 mg/kg/d CFAAM, respectively 
showed no significant (p<0.05) increase in body 
weight after weeks 2, 3, and 4 when compared 
with their respective body weight at week 1. 
Contrary, BPH induced rats treated with 600 
mg/kg/d CFAAM showed significant (p<0.05) 
increase in their body weight after weeks 2, 3, 
and 4, respectively when compared with its 
body weight after week 1. 
 
Effects of Combined Ethanolic Extract of F. 
africana and A. mauritianum Leaves 
(CFAAM) on the Prostate Weight and 
Prostate Index of Benign Prostatic 
Hyperplasia (BPH) Rats: It was observed 
that there were significant (p<0.05) increases in 
the prostate weight of the BPH control, standard 
control (Finasteride) and BPH induced and BPH 
induced rats treated with 200 and 600 mg/kg/d 
CFAAM, respectively when compared with the 
normal control rats (Table 2). BPH induced rats 
treated with 5 mg/kg/d Finasteride (standard 
control) and 600 mg/kg/d CFAAM, respectively 
showed significant (p<0.05) decrease in 
prostate weight relative to the BPH control rats. 
Whereas, BPH induced rats treated with 200 
mg/kg/d CFAAM showed no significant (p>0.05) 
decrease in prostate weight when compared 
with BPH control. Also, it was observed that BPH 
induced rats treated with 600 mg/kg/d CFAAM 
had significantly (p<0.05) lower prostate weight 
when compared with the BPH induced rats 
treated with 5 mg/kg/d Finasteride (standard 
control). Also, the prostate index of benign 
prostate hyperplasia (BPH) induced rats treated 
with CFAAM showed that the induction caused 
significant (p<0.05) increase in the prostate 
index relative to the normal control rats with 
that of the BPH control having highest increase.  
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Table 1: Body weight of benign prostatic hyperplasia induced rats treated with combined 
ethanolic extract of F. africana and A. mauritianum leaves (CFAAM) 
Weeks  Changes in body weight (g) 










Week 1 147.37 ± 8.17a 138.8 ± 9.04a 144.23 ± 8.50a 143.62 ± 8.32a 136.67 ± 9.52a 
Week 2 151.30 ± 155ab 143.3 ± 8.72ab 147.15 ± 9.66a 159.37 ± 10.49a 152.25 ± 8.18b 
Week 3 172.88 ± 9.09b 160.38 ± 6.53b 166.12 ± 7.98a 166.52 ± 7.65a 161.68 ± 7.26b 
Week 4 171.42 ± 7.08b 157.88 ± 7.90b 160.93 ± 8.53a 164.50 ± 9.14a 161.18 ± 8.40b 
Values are presented as mean ± standard deviation (n = 6), Values with different superscripts are significantly different 
(p<0.05) 
 
Table 2: Prostate weight and prostate index of benign prostatic hyperplasia (BPH) 
induced rats treated with combined ethanolic extract of F. africana and A. mauritianum 
leaves (CFAAM) 
Treatment groups Prostate weight (g) Prostate index (PI) 
Normal Control 0.233  ±  0.022a 0.136  ±  0.020a 
BPH Control 0.667  ±  0.037c 0.422  ±  0.030c 
Standard Control 0.500  ±  0.034b 0.311  ± 0.012b 
200 mg/kg/d CFAAM 0.533  ±  0.025bc 0.324  ±  0.020b 
600 mg/kg/d  CFAAM 0.300  ±  0.023a 0.186  ±  0.013a 
Values are presented as mean ± standard deviation (n = 6), Values with different superscripts are significantly different 
(P<0.05) 
 
However, treatment with the CFAAM caused 
significant (p<0.05) reduction of the prostate 
index of the standard control treated with 
Finasteride and BPH induced rats treated with 
200 and 600 mg/kg/d CFAAM relative to the 
BPH control rats. It was also observed that the 
BPH induced rats treated with 600 mg/kg/d 
CFAAM showed no significant (p>0.05) increase 
in the prostate index when compared with 
normal control rats. 
 
Inhibitory Effects of Combined Ethanolic 
Extract of F. africana and A. mauritianum 
Leaves on Prostate Weight and Prostate 
Index of Benign Prostatic Hyperplasia 
Induced Rats: The results in Table 3 showed 
that CFAAM possesses dose-dependent 
inhibitory effects on prostate weight and 
prostate index of benign prostatic hyperplasia 
induced rats. The CFAAM at 200 mg/kg/d had 
lower inhibitory effects on the prostate weight 
and prostate index when compared with 
standard control treated with 5 mg/kg/d of 
Finasteride. However, BPH induced rats treated 
with 600 mg/kg/d CFAAM had greater 
reductions in prostate weight (84.54 %) and  
 
 
prostate index (82.52 %) relative to the 
standard control treated with Finasteride. 
 
Table 3: Inhibitory effects of a combined 
extract of F. africana and A. mauritianum 
leaves (CFAAM) on prostate weight (PW) 
and prostate index (PI) of benign 
prostatic hyperplasia (BPH) induced rats  
Treatment Groups Degree of  
inhibition (%) 
PW PI 
Normal control - - 
BPH control - - 
Standard control 38.48 38.81 
200 mg/kg/d CFAAM 35.8 34.27 
600 mg/kg/d CFAAM 84.54 82.52 
PW = Prostate weight; PI = Prostate index 
 
Effects of Combined Ethanolic Extract of F. 
africana and A. mauritianum Leaves (on 
the Serum Testosterone (TT) Levels of 
Benign Prostatic Hyperplasia Induced 
Rats: The testosterone concentrations in BPH 
induced rats treated with CFAAM showed that 
the BPH of the control rats had significantly 
(p<0.05) elevated testosterone concentrations 
relative to the normal control (Figure 1). The 
standard control that received 5 mg/kg/d 
Finasteride had no significant (p>0.05) 
3896 
Uroko et al.                                                                                                                              3893 
Animal Research International (2020) 17(3): 3892 – 3902 
reduction in testosterone concentration, while 
all the CFAAM-treated groups showed no 
significant (p>0.05) increase in testosterone 
concentrations when compared with the normal 
control. BPH induced rats treated with 
Finasteride, 200 and 600 mg/kg/d CFAAM-
treated rats had significantly (p<0.05) reduced 
testosterone concentrations when compared 
with the BPH control. The testosterone 
concentrations the CFAAM-treated rats were 
significantly (p<0.05) elevated relative to the 
standard control rats. 
 
 
Figure 1: Testosterone (TT) concentrations in 
benign prostatic hyperplasia (BPH) induced 
rats treated with combined ethanolic extract of 
F. africana and A. mauritianum leaves (CFAAM) 
Key: Each bar represent mean ± standard deviation (n = 
6), Bars with different superscripts are significantly different 
at p<0.05 
 
Effects of Combined Ethanolic Extract of F. 
africana and A. Mauritianum Leaves 
(CFAAM) on the Serum Dihydrotestosterone 
(DHT) Levels of Benign Prostatic Hyperplasia 
Induced Rats: The dihydrotestosterone (DHT) 
concentrations indicated a significant (p<0.05) 
increase in DHT concentrations of BPH control, 
standard control (Finasteride) and BPH induced 
rats treated with 200 mg/kg/d CFAAM, 
respectively when compared with the DHT 
concentration of the normal control (Figure 2). 
However, there were significant (p<0.05) 
decreases in the DHT concentrations of the 
standard control, and BPH induced rats treated 
with 200 and 600 mg/kg/d CFAAM relative to 
the BPH control rats. The DHT concentrations 
observed in the BPH induced rats treated with 
the CFAAM were lower than the DHT 
concentration of BPH induced rats treated with 
5 mg/kg/d Finasteride, with the DHT 
concentration of the BPH induced rats treated 




Figure 2: Dihydrotestosterone (DHT) 
concentrations in benign prostatic hyperplasia 
(BPH) induced rats treated with combined 
ethanolic extract of F. africana and A. 
mauritianum leaves (CFAAM) Key: Each bar 
represent mean ± standard deviation (n = 6), Bars with 
different superscripts are significantly different at p<0.05 
 
Effects of Combined Ethanolic Extract of F. 
africana and A. mauritianum Leaves 
(CFAAM) on the Serum Estradiol (E2) 
Levels of Benign Prostatic Hyperplasia 
Induced Rats: It was evidenced that the BPH 
induction caused significant (p<0.05) increases 
in the estradiol concentrations in all the induced 
rats when compared with the normal control 
(Figure 3).  
 
 
Figure 3: Estradiol concentrations in benign 
prostatic hyperplasia (BPH) induced rats 
treated with combined ethanolic extract of F. 
africana and A. mauritianum leaves (CFAAM) 
Key: Each bar represent mean ± standard deviation (n = 
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Treatment of the standard control rats with 5 
mg/kg body weight of Finasteride and the 
groups treated with 200 and 600 mg/kg/d of 
CFAAM, respectively reduced estradiol 
concentrations significantly (p<0.05) relative to 
the BPH control. The CFAAM-treated BPH 
induced rats had no significantly (p>0.05) lower 
estradiol concentrations when compared with 




This study evaluated the effects of CFAAM on 
sex steroid hormone levels and prostate indices 
of benign prostatic hyperplasia induced rats 
using testosterone propionate injection. Benign 
prostatic hyperplasia (BPH) is a common 
prostate disorder in ageing men that greatly 
impair quality of life, and shorten their life 
expectancy due to lack of a cure, high cost of 
treatments and limited available effective 
treatment options.  Abnormal levels of sex 
steroid hormones including testosterone, (DHT) 
and estradiol (E2) have been implicated in the 
initiation and progression of BPH in ageing men 
via the induction of prostate epithelial cell 
growth and proliferation. The conversion of 
testosterone to DHT by 5α-reductase enzymes 
and interaction of the DHT with its androgen 
receptors promotes protein synthesis, epithelial 
cell growth of the prostate and prostate 
enlargement (Carson and Rittmaster, 2003; Cai 
et al., 2018). 
The high percentage yield of the CFAAM 
recorded in this indicates that F. africana and A. 
mauritianum leaves are rich in polar 
phytoconstituents extractable with ethanol. 
The persistent increase in the body 
weight of the BPH induced rats similar to the 
normal control showed that BPH has no effects 
on the body weight of the rats. The BPH did not 
alter appetite of the rats for food, loss of body 
weight, and similarly, CFAAM had no effects on 
the body weight. The extract was unable to 
induce excessive weight gain through increased 
food intake and storage in the adipose tissues 
and vice versa and agreed with the findings of 
Cai et al. (2018). 
The elevated concentration of 
testosterone in the benign prostatic hyperplasia 
induced rats showed that the administration of 
testosterone propionate injection resulted in the 
high serum level of testosterone responsible for 
the initiation and progression of BPH. This 
elevated serum level of testosterone 
predisposed the rats to the development of BPH 
because it can be converted to a more active 
DHT when acted upon by 5α-reductase enzymes 
which may induce increased protein synthesis, 
growth, and proliferation of epithelial and 
stromal tissues. However, the significant 
reduction in the testosterone levels in the BPH 
induced rats treated with CFAAM was similar to 
Finasteride-treated rats may be attributed to the 
anti-benign prostatic hyperplasia activities of its 
phytoconstituents such as steroids, phenols and 
flavonoids (Banso and Adeyemo, 2004; Kouadio 
et al., 2017). The effect of CFAAM was not 
dose-dependent and can substitute for 
Finasteride as testosterone lowering agent in 
patients with benign prostatic hyperplasia. The 
reductions of testosterone level by CFAAM 
prevented BPH development and progression 
and it was consistent with the findings that 
drugs that down-regulate testosterone and DHT 
prevent BPH development (Patil et al., 2016). 
The significantly elevated DHT 
concentration in the BPH control rats showed 
that 5α-reductase enzymes were able to convert 
the excess testosterone to DHT unhindered. The 
excess DHT concentrations in the rats promoted 
benign prostatic hyperplasia and decreased the 
quality of life. This is because excess DHT binds 
to androgen receptors and stimulate cellular 
proliferation factors and progression of BPH 
synthesis was in line with the findings of Da 
Silva and De Souza (2019). Whereas, the 
significant reduction in DHT concentrations in 
the Finasteride and the CFAAM- treated rats, 
respectively showed that they were able the 
activities of 5α-reductase enzymes and impaired 
conversion of testosterone to DHT. The CFAAM 
exhibited a dose-dependent reduction of DHT 
with the CFAAM possessing high activities far 
above Finasteride at high concentration and can 
be more effective in the management of benign 
prostatic hyperplasia than Finasteride. The low 
DHT concentrations in the CFAAM-treated rats 
did not promote prostate growth by induction of 
differentiation and proliferation of epithelial 
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tissues of the prostates. This was in agreement 
with previous findings of that the conversion of 
testosterone to dihydrotestosterone decreases 
the levels of dihydrotestosterone, prevents 
enlargement of the prostatic epithelium and 
reduction in the prostate size (Nickel et al., 
2011; Wu et al., 2014). 
Estradiol is mainly produced in the 
prostate gland by the action of aromatase which 
converts much of the circulating testosterone to 
estradiol for spermatogenesis and maintenance 
of sperm quality (Mäkelä et al., 2000). It has 
two receptors denoted by ERα expressed in a 
few stromal cells, and ERβ, largely expressed in 
the epithelium and some stromal cells. 
Normally, when estradiol binds to ERα, it 
stimulates cell proliferation and inflammation of 
the prostate, while binding of estradiol to ERβ 
counters the effects of ERα to estradiol by 
exhibiting anti-proliferative and anti-
inflammatory activities (Ellem and Risbridger, 
2009; Da Silva and De Souza, 2019). However, 
in ageing men, under high estradiol 
concentration and in BPH condition, ERα is 
highly expressed and actions of ERα – estradiol 
predominate over ERβ – estradiol and promotes 
differentiation and proliferation of prostate 
tissues and prostate inflammation leading 
prostate enlargement (Hewitt et al., 2010). The 
elevated estradiol concentrations in the BPH 
control rats relative to the normal control rats 
showed that much of the testosterone produced 
in the rats due to testosterone propionate 
injection were converted to estradiol by the 
actions of aromatase enzymes in the prostate. 
The increased estradiol concentration may have 
interacted with estrogen receptor (ERα) and 
induced prostate cell differentiation and 
proliferation and eventual prostate enlargement. 
On the contrary, the dose-dependent decrease 
in the estradiol concentration of Finasteride and 
CFAAM, respectively relative to the BPH control 
may be attributed to the therapeutic effects of 
the bioactive constituents like steroids, phenolic 
and flavonoids present in each of the plants. 
Plant extracts rich in steroids like beta-sitosterol 
have been demonstrated to prevent benign 
prostatic hyperplasia progression by reducing 
the circulating level of dihydrotestosterone 
(DHT) which inhibits prostate tissue growth 
(Bishnoi et al., 2017). 
The reductions in the serum estradiol 
levels are indicative of a reduction in prostate 
volume which is in line with the report of 
Vermeulen et al. (2002) that most patients with 
larger volumes of BPH have increased levels of 
serum estradiol and vice versa. The combined 
ethanolic extract reduced the testosterone 
concentrations available as a substrate for 
conversion to estradiol by aromatase enzymes. 
Sequel to this, CFAAM-treated BPH induced rats 
had reduced level of adverse health effects 
associated with benign prostatic hyperplasia. 
However, none of the treatments was able to 
maintain estradiol concentration equivalent to 
the normal control and predisposed the rats to 
some levels of adverse health effects of 
increased serum estradiol concentrations.  
The highly elevated prostate weight and 
prostate index in the BPH control rats showed 
that the testosterone propionate caused benign 
prostatic hyperplasia in the rats. These rats with 
an enlarged prostate suffered urinary difficulties 
such as increased urinary urgency, and 
incomplete emptying of the bladder and 
impaired their quality of life. This was in 
agreement with the finding of Sayed et al. 
(2016) that rats received testosterone injection 
for 28 consecutive days without treatment 
showed increased prostate weight. The 
reductions in the prostate weight and prostate 
index in the standard control treated with 
Finasteride and CFAAM-treated rats relative to 
the BPH control may be attributed to anti-
benign prostatic hyperplasia activities of each of 
the treatments in accordance with the findings 
of Ishola et al. (2018). CFAAM effectively shrunk 
the enlarged prostate most especially at high 
dose (600 mg/kg/d) and suggested that 600 
mg/kg/d was the effective dose of  CFAAM that 
shrink enlarged prostate to normal size as 
indicated in the normal control. CFAAM possess 
better anti-benign prostatic hyperplasia activity 
at a high dose than Finasteride and represent a 
more viable option for the treatment of BPH. 
However, further research is needed to identify 
and characterise the actual bioactive 
phytoconstituents such as steroids, phenols and 
flavonoids responsible for the observed anti-
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benign prostatic hyperplasia activities.  CFAAM 
achieved greater reductions in prostate weight 
and prostate index possibly by inhibiting the 
differentiation and proliferation of epithelial and 
stromal tissues of the prostate. The high 
inhibitory effects of CFAAM on the prostate 
weight and prostate index at a high dose further 
confirm that CFAAM exhibited better anti-benign 
prostatic hyperplasia than Finasteride with low 
anti-benign prostatic hyperplasia activities. The 
reduction of prostate weight and prostate index 
is indicative that the combined ethanolic extract 
possesses anti-benign prostatic hyperplasia 
activity in line with the previous report by Cai et 
al. (2018) that reduction of prostate weight and 
prostate index is attributed inhibition of benign 
prostatic hyperplasia. 
 
Conclusion: The findings of this study revealed 
that the combined ethanolic extract of F. 
africana and A. mauritianum leaves reduce 
excessive concentrations of steroid hormones 
such as testosterone, dihydrotestosterone, and 
estradiol implicated in the pathogenesis of 
benign prostatic hyperplasia. The combined 
ethanolic extract lowers prostate weight and 
prostate index and showed very high inhibitory 
effects on the prostate weight and prostate 
index at high concentration. Further research 
should be conducted on this combined ethanolic 
extract to identify, isolate, and characterise its 




The medicinal plants used in this study were 
identified and authenticated by Dr. Ibe K. 
Ndukwe, a taxonomist at the Department of 
Forestry, College of Natural Resources and 
Environmental Management, Michael Okpara 
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